GPT and anemia (phenotype): In the safety analysis, larotrectinib was well tolerated with grade 4 adverse events in 1% and grade 3 in 13% of patients (grade 3–4: neutropenia in 2%, anemia in 2% and elevation of aspartate aminotransferase, AST, or alanine aminotransferase, ALT, in 3%), without treatment-related deaths.